9 results about "Existing Treatment" patented technology

The utility model discloses a therapeutic instrument, relates to medical instrument technical field, the therapeutic instrument includes therapeutic head, handle and elastic piece, the therapeutic head is equipped with connecting shaft, connecting shaft outer wall is equipped with groove, therapeutic head and handle detachable connection, handle is equipped with connecting hole, handle is equipped with mounting groove, the mounting groove is located in connecting hole inner peripheral surface, and the elastic piece is equipped with elastic piece. The mounting groove is communicated with the connecting hole, and the elastic piece is mounted in the mounting groove; when the connecting shaft is inserted into the connecting hole, the elastic piece deforms and is clamped into the groove. When the connecting shaft is pulled out of the connecting hole, the elastic piece deforms, and the groove is separated from the elastic piece. According to the technical scheme provided by the utility model, the problems that the existing treatment head and the handle are connected by adopting a buckle, the connection or the unlocking each time needs to be performed by pressing a key, more time needs to be consumed, and the operation is not very convenient are solved.

The invention discloses an application of an lncRNA-MALAT1 / miR-145 / BNIP3 regulation axis in preparation of a medicine for treating hemorrhagic shock ischemia reperfusion intestinal injury. In existing treatment, conventional liquid resuscitation easily causes serious inflammation and pathological apoptosis, the intestinal barrier repair effect is limited, and the molecular mechanism is not completely clarified. The invention discloses that a regulatory axis participates in an intestinal injury process through a ceRNA mechanism (MALAT1 is used as miR-145 sponge to inhibit regulation of BNIP3 and mediate controlled programmed cell death instead of pathological apoptosis), and provides a new molecular target for treatment. The medicine aiming at the regulation shaft can relieve inflammatory response, reduce pathological apoptosis and promote intestinal barrier repair, and has a good application prospect.

The invention relates to a biomarker combination for treating SHH subtype medulloblastoma, and aims to solve the problems that existing treatment targets are deficient, the curative effect is limited and precise treatment is insufficient. The invention reveals that an m6A-YTHDF2 signal axis is a novel treatment target of SHH-MB for the first time, the YTHDF2 regulates and controls the expression of a downstream target gene DENND2A through an m6A dependency mode, the high expression of the YTHDF2 is related to poor prognosis of a patient, and knock-down of the YTHDF2 can significantly inhibit the proliferation and balling ability of SHH-MB cells. According to the invention, the TET-ON regulated SHH-MB cell line capable of inducing to knock down YTHDF2 is constructed, and a tool is provided for drug screening; it is clear that a YTHDF2 inhibitor (such as DC-Y13-27 and the like) can achieve the anti-tumor effect by down-regulating DENND2A expression, and the drug sensitivity of SHH-MB tumor cells to a Hedgehog signal channel small molecule inhibitor Vismodegib (GDC-0449) is improved.

The invention discloses a compound for treating leukemia. According to the application, the compound 526 with high activity is identified through high-throughput screening and functional verification. The compound 526 can obviously kill AML cells and prolong the lifetime of a patient, is expected to provide a new strategy for overcoming the existing treatment bottleneck, and has a wide application prospect.

The invention provides application of chidamide or a derivative thereof in preparation of a medicine for preventing and / or treating acute T lymphocytic leukemia. According to statistics of curative effect data of grouped clinical patients, compared with an existing treatment scheme (the curative effect is 20-30%) for treating acute T-ALL, the pharmaceutical composition provided by the invention has the advantages that the curative effect can be improved to 75%, and remarkable clinical benefits are brought.

The utility model discloses a treatment head and noninvasive radio frequency therapeutic apparatus relates to medical instrument technical field, the treatment head includes base, contact portion and support frame, the base is equipped with the mounting cavity, the one end of mounting cavity is equipped with the opening, the contact portion is connected with base and covers the opening, is used for tightly contact with skin surface to provide radio frequency energy to skin, and the support frame is equipped with the support frame. And the support frame at least abuts against the middle part of the contact part and is nested in the mounting cavity. According to the technical scheme provided by the utility model, the problems that the contact part of the existing treatment head is easy to sink inwards after being used for a long time, so that charges on the contact part are not uniformly distributed, the local overheating edge effect is generated, and the skin is scalded are solved.

This invention discloses an injectable hydrogel loaded with 4-octyl itaconic acid, its preparation method, and its applications, belonging to the field of biomedical materials technology. The injectable hydrogel is formed by enzymatic cross-linking of a hyaluronic acid-tyramine complex to create a three-dimensional network, with 4-octyl itaconic acid encapsulated within this network structure. This invention allows for precise implantation of the hydrogel into the intervertebral disc lesion via minimally invasive injection, achieving local high-concentration drug accumulation. The three-dimensional network of the hydrogel serves as a drug reservoir, enabling continuous and controllable release of 4-OI, prolonging the drug's duration of action and achieving long-term therapeutic effects. Simultaneously, the loaded 4-OI specifically activates the Nrf2 / GPX4 antioxidant pathway in nucleus pulposus cells, mechanistically antagonizing ferroptosis and matrix degradation, thus achieving a dual function of mechanical support and biological therapy. It exhibits good biocompatibility and solves the problems of difficult targeted drug delivery, short-lived efficacy, and lack of disease-modifying effects in existing treatments for intervertebral disc degeneration.

The utility model discloses a treatment head and therapeutic instrument, relates to medical instrument technical field, the treatment head includes the casing, drive subassembly, rotatory subassembly and transducer, the casing has the accommodation space, drive subassembly is installed in the accommodation space and is connected with the casing, rotatory subassembly is installed in the accommodation space, and the transducer is connected with the rotatory subassembly. The rotating assembly is connected to the moving end of the driving assembly, the rotating assembly is provided with a connecting piece, the connecting piece is provided with a rotating center, the transducer is connected to the connecting piece, the transducer is provided with a center shaft, and the center shaft of the transducer and the rotating center of the connecting piece are arranged in a non-coaxial mode; wherein the driving assembly drives the rotating assembly to drive the transducer to move in the first direction, and the rotating assembly drives the connecting piece to drive the transducer to eccentrically rotate. According to the technical scheme provided by the utility model, the problems of heavy structure and large occupied space of the existing treatment head adopting a double-screw scheme are solved.

The invention relates to the technical field of biomedicine, and particularly discloses application of MIDN protein in diagnosis and treatment of glioma. Glioblastoma (GBM) is the most common malignant glioma in the central nervous system and accounts for more than 50% of all glioma, and the existing treatment means face challenges of high drug resistance, poor prognosis and the like. Based on the association between protein degradation imbalance and tumor occurrence and development, the invention finds that MIDN can capture substrate protein through a Catch structural domain thereof and degrade carcinogenic substrate molecules (such as PPDPF) through a non-ubiquitin proteasome pathway, thereby inhibiting the malignant progression of glioma.